Pharma BD Deal Intelligence
Amgen's $16B Immunex buy turned Enbrel into a multi-decade, $80B+ cumulative-revenue franchise via aggressive patent-thicket defense — one of biotech's better-aged mega-deals despite a large day-one IPR&D writedown.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Etanercept was approved for RA in November 1998, juvenile RA in May 1999, psoriatic arthritis in January 2002, ankylosing spondylitis in July 2003, and plaque…
Amgen completed its acquisition of Immunex on July 16, 2002, with each Immunex share exchanged for 0.44 Amgen shares plus $4.50 cash; CEO Kevin Sharer said…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Amgen Inc. completed its acquisition of Immunex Corporation on July 15, 2002, in a transaction valued at approximately $16 billion — the largest biotechnology merger at the time. Each Immunex share was exchanged for 0.44 Amgen shares plus $4.50 in cash. The deal followed FTC clearance, which required Amgen to divest Leukine to Schering AG and license TNF-inhibitor intellectual property to Serono, and brought the rheumatoid-arthritis biologic Enbrel (etanercept) into Amgen's portfolio.
Amgen's $16B Immunex buy turned Enbrel into a multi-decade, $80B+ cumulative-revenue franchise via aggressive patent-thicket defense — one of biotech's better-aged mega-deals despite a large day-one IPR&D writedown.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Immunex Corporation (this deal) | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2002 deals · Amgen Inc. deals · Immunology deals